Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat

Autor: David L. Bushnell, M. Sue O'Dorisio, K D Zamba, Thomas M. O'Dorisio, Janet H Pollard, Mark T. Madsen, Yusuf Menda
Rok vydání: 2021
Předmět:
Male
endocrine system
Cancer Research
Single Photon Emission Computed Tomography Computed Tomography
endocrine system diseases
medicine.drug_class
Biological Availability
Pilot Projects
Neuroendocrine tumors
Octreotide
Multimodal Imaging
Pheochromocytoma
Norepinephrine
Stomach Neoplasms
Original Research Articles
Neuroblastoma
Intestinal Neoplasms
Outcome Assessment
Health Care
medicine
Humans
Radiology
Nuclear Medicine and imaging
Neoplasm Metastasis
neoplasms
Vorinostat
Neoplasm Staging
Pharmacology
Chemistry
Somatostatin receptor
Liver Neoplasms
Histone deacetylase inhibitor
General Medicine
Middle Aged
medicine.disease
Histone Deacetylase Inhibitors
Pancreatic Neoplasms
3-Iodobenzylguanidine
Neuroendocrine Tumors
Oncology
Cancer research
Female
Histone deacetylase
Radiopharmaceuticals
hormones
hormone substitutes
and hormone antagonists
medicine.drug
Zdroj: Cancer Biother Radiopharm
ISSN: 1557-8852
1084-9785
Popis: Background: Histone deacetylase (HDAC) inhibitors have been shown in preclinical studies to upregulate norepinephrine transporters in neuroblastoma and pheochromocytoma, and somatostatin receptors in pulmonary carcinoid, small cell lung cancer, and pancreatic neuroendocrine malignancies. This pilot imaging study in humans focuses on midgut neuroendocrine carcinoma metastatic to the liver, evaluating the effect of pretreatment with the HDAC inhibitor vorinostat on uptake of (123)I-MIBG and (68)Ga-DOTATOC. Materials and Methods: Multiple midgut neuroendocrine liver metastases in clinically stable subjects were imaged with (123)I-MIBG and (68)Ga-DOTATOC before and after a 4-d course of vorinostat. Scans were performed with strict attention to detail and timed about 1 month apart occurring just before monthly long-acting octreotide administrations. Uptake changes in tumor and normal liver parenchyma were assessed on positron emission computed tomography (PET/CT) with standardized uptake values and on single photon emission computed tomography (SPECT) with qualitative ratio images. Results: The experimental units were metastatic liver lesions within patients (n = 50). There was no significant difference in administered activity or uptake time between pairs of scans for either radiotracer. Statistically significant increase in maximum standardized uptake values (SUV(max)) averaged over all lesions was noted on the (68)Ga-DOTATOC PET scans (+11%, p
Databáze: OpenAIRE
Externí odkaz: